New combo therapy aims to stop sarcoma return in kids and young adults

NCT ID NCT03465592

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug nivolumab can be safely given after a half-matched bone marrow transplant to help prevent sarcomas from coming back. It includes children and young adults up to age 50 who have already had the transplant and are at high risk of relapse. Researchers will monitor side effects and overall survival to see if this approach works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood neoplasm sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA SOLID TUMOR, ADULT SOLID TUMOR, CHILDHOOD

Contacts and locations

Locations

Albert Einstein College of Medicine, Children's Hospital at Montefiore
RECRUITING

The Bronx, New York, 10467, United States
Johns Hopkins All Children's Hospital
ACTIVE_NOT_RECRUITING

St. Petersburg, Florida, 33701, United States
Johns Hopkins Hospital
RECRUITING

Baltimore, Maryland, 21287, United States
New York Medical Center/ Maria Fareri Children's Hospital
RECRUITING

Valhalla, New York, 10595, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.